Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia Academic Article uri icon

Overview

MeSH Major

  • CD40 Ligand
  • Cancer Vaccines
  • Interleukin-2
  • Leukemia, B-Cell
  • Leukemia, Lymphocytic, Chronic, B-Cell

abstract

  • These results suggest that immune responses to B-cell chronic lymphocytic leukemia can be obtained with human CD40 ligand/human interleukin-2-expressing s.c. vaccines but that these responses are transient. High levels of circulating regulatory T cells are present, and it will be of interest to see if their removal in vivo augments and prolongs the antitumor immune response.

publication date

  • October 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-05-0484

PubMed ID

  • 16203783

Additional Document Info

start page

  • 6916

end page

  • 23

volume

  • 11

number

  • 19 I